TP53 and carcinoma: In carcinoma of the LUS, Jacques et al. found that 60% (3/5) of cases had abnormal p53 protein [3]; Jiko et al. found a p53 mutation in 38% (3/8) of cases [9]; and Watanabe et al. found overexpression of p53 in 61.5% (8/13) of cases, a frequency higher than that (18.2%, 6/33) in non-LUS endometrial cancer [6].